BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ceramide NanoLiposome (Ceraxa) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ceramide NanoLiposome (Ceraxa)\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04716452-3058@assetmemo.bio
DTSTAMP:20261121T005951Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Ceramide NanoLiposome (Ceraxa): Phase 1 readout est. (NCT04716452)
DESCRIPTION:Ceramide NanoLiposome (Ceraxa)\, phase 1\, Acute Myeloid Leukem
 ia.\nStudy: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relap
 sed/Refractory Acute Myeloid Leukemia\nEstimated primary completion: 30 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ceramide-
 nanoliposome-ceraxa#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04716452
URL:https://assetmemo.bio/drug/ceramide-nanoliposome-ceraxa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
